Terns Pharmaceuticals filed its second amendment to third-party tender offer disclosures this week, adjusting terms in its pending acquisition of Genfit SA, the French metabolic disease specialist. The filing marks the latest procedural step in a $360 million all-cash transaction announced in October that would hand Terns full ownership of elafibranor, a late-stage therapy for primary biliary cholangitis currently under FDA review with a March PDUFA date.

The SC TO-T/A amendment landed without accompanying press release, typical for technical corrections to offer timing or regulatory language rather than material deal restructuring. Terns opened its tender at $9.23 per Genfit ordinary share in late October with an initial expiration set for mid-December. The original offer represented a 93 percent premium to Genfit's pre-announcement close and valued the combined entity's PBC franchise at roughly four times 2026 consensus revenue for elafibranor, assuming approval.

The amendment matters because Terns is executing a cross-border tender with dual NASDAQ and Euronext Paris components while carrying $240 million in net cash against a $580 million market cap before deal announcement. The company is effectively wagering its balance sheet on a single FDA decision in three months. Elafibranor posted positive Phase III data in PBC patients with inadequate ursodeoxycholic acid response, hitting its primary endpoint with 51 percent biochemical response versus 4 percent on placebo. But the drug failed a separate NASH trial in 2020, and Genfit's enterprise value collapsed 87 percent between 2019 and the Terns bid.

Two scenarios command attention for allocators positioned in small-cap biotech. First, the March PDUFA date creates a binary event where approval likely doubles Terns' equity value overnight while rejection vaporizes the deal thesis and leaves the company with a $120 million burn rate against diminished cash. Second, the tender structure allows Terns to walk if it fails to secure 67 percent acceptance, the French takeover threshold. Genfit shareholders tendered 71 percent by the initial November deadline, leaving a narrow margin for defections if revised terms displease remaining holders.

Operators should track three near-term events: the amended tender expiration likely landing before December 20, the FDA's advisory committee calendar for any elafibranor panel scheduling, and Terns' cash position in its next 10-Q due February. The company has guided to $90-100 million in 2024 operating expense, implying runway into late 2026 if the deal closes and no additional capital raise materializes.

Genfit trades at $8.91 on Euronext Paris as of Thursday, 3.5 percent below the tender price, suggesting modest arb spread for a deal that either closes in thirty days or collapses on regulatory risk no one can hedge.